A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.
Author | |
---|---|
Abstract | :
The burden of type 2 diabetes mellitus is growing rapidly, particularly in the Asia-Pacific region. The aim of this international, large-scale, observational study was to investigate the efficacy and tolerability of the antidiabetic agent acarbose as add-on or monotherapy in a range of patients with type 2 diabetes, including those with cardiovascular morbidities. The majority of practices were included from high-burden regions (predominantly those in the Asia-Pacific region). |
Year of Publication | :
2013
|
Journal | :
Clinical drug investigation
|
Volume | :
33
|
Issue | :
4
|
Number of Pages | :
263-74
|
ISSN Number | :
1173-2563
|
URL | :
https://dx.doi.org/10.1007/s40261-013-0063-3
|
DOI | :
10.1007/s40261-013-0063-3
|
Short Title | :
Clin Drug Investig
|
Download citation |